Switch to:
More From Other Websites
Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 20, 2017 Jun 20 2017
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 19, 2017 Jun 19 2017
Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying Jun 12 2017
Alkermes Commences Phase III Study for Schizophrenia Drug Jun 12 2017
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder Jun 12 2017
Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference Jun 08 2017
Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients Jun 08 2017
Alkermes Gets FDA Nod for Two Month Dose of Aristada Jun 07 2017
Can Alkermes' Latest Approval Spark a Rally? Jun 07 2017
FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia Jun 06 2017
Key FDA Events to Watch Out for in Jun 2017 Jun 05 2017
Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue? May 31 2017
Alkermes’ Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference May 30 2017
Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President,... May 30 2017
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : May 26, 2017 May 26 2017
Why These Drug Stocks May Surge May 15 2017
Big Week Ahead for Alkermes May 15 2017
Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting May 11 2017
3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018 May 04 2017
[$$] Three Top Picks in Smaller Pharma May 02 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK